Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 956Neoplasms 755Carcinoma, Non-Small-Cell Lung 742Prostatic Neoplasms 569Colorectal Neoplasms 499Lung Neoplasms 444Neoplasm Metastasis 400Multiple Myeloma 371Leukemia, Myeloid, Acute 351Ovarian Neoplasms 307Pancreatic Neoplasms 301Melanoma 273Squamous Cell Carcinoma of Head and Neck 257Recurrence 248Carcinoma, Hepatocellular 229Glioblastoma 223Brain Neoplasms 219Head and Neck Neoplasms 199Triple Negative Breast Neoplasms 198Carcinoma, Renal Cell 197Precursor Cell Lymphoblastic Leukemia-Lymphoma 190Lymphoma 188Stomach Neoplasms 186Endometrial Neoplasms 177Lymphoma, Non-Hodgkin 172Sarcoma 168Glioma 165Uterine Cervical Neoplasms 160Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 157

Interventions

remdesivir 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Respiratory Syncytial Virus Infections × 90 days × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡